Please login to the form below

Not currently logged in
Email:
Password:

Relypsa

This page shows the latest Relypsa news and features for those working in and with pharma, biotech and healthcare.

Vifor wins European approval for Veltassa

Vifor wins European approval for Veltassa

The go-ahead is a significant milestone for Vifor Pharma Group - who acquired Veltassa from Relypsa - as it marks the drug’s first regulatory approval outside the US. ... Relypsa plans to submit Veltassa applications in other markets worldwide and the

Latest news

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Deal Watch July 2016 Deal Watch July 2016

    Veltassa was approved in late 2015 and Relypsa achieved revenues of $30.9m since its launch, making the 50x revenue multiple paid look relatively attractive. ... Licence, co-development, equity stake. 2, 561. Relypsa/ Galenica. Veltassa - Potassium binder

  • Pharma deals in August 2015 Pharma deals in August 2015

    Collaboration. 219. Relypsa. Vifor Fresenius. Patiromer oral suspension in treating hyperkalemia.

  • Pharma deals during November 2013 Pharma deals during November 2013

    Relypsa, a late-stage biotech developing a phase III treatment for hyperkalemia, get its IPO away but at a significantly reduced price (from a range of $16 to $19 per share

  • Pharma deals during October 2013 Pharma deals during October 2013

    Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

  • OPKO appoints vice president of medical affairs OPKO appoints vice president of medical affairs

    Dr Douglass Laidlaw brings experience from Relypsa and Sanofi. Miami-based OPKO Health has appointed Dr Douglass Laidlaw as vice president of medical affairs. ... He previously served as Relypsa's executive director, medical affairs and Sanofi's national

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics